12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-01), Cara Therapeutics's 12-1 Month Momentum % is -78.33%.
The industry rank for Cara Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
CARA's 12-1 Month Momentum % is ranked worse than 89.78% of 1478
companies
in the Biotechnology industry
Industry Median: -20.535
vs CARA: -78.33
Competitive Comparison of Cara Therapeutics's 12-1 Month Momentum %
For the Biotechnology subindustry, Cara Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cara Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's 12-1 Month Momentum % falls into.
Cara Therapeutics (NAS:CARA) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cara Therapeutics 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Cara Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cara Therapeutics (Cara Therapeutics) Business Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARA has been successfully added to your